Pharmalink AB Receives Patent for Nefecon(R) Principle
- Japanese Grant Supports Asian Partnering Programme
Pharmalink AB announced today that it has been granted Japanese Patent No4326696, "Methods and means for treating glomerulonephritis" for its productNefecon(R) which is being developed to treat IgA nephropathy, aglomerulonephritis leading to end-stage renal disease (ESRD). Counterparts ofthe patent have been issued for other territories including the EU, US andChina.
Pharmalink's Managing Director Johan Haggblad said, "We now have IPprotection for the Nefecon(R) principle in the major pharmaceutical markets.We are particularly happy about the addition of Japan as we are activelyseeking product development partners for Asia. Asia is of high importance forNefecon(R) as Japan and China represent areas with significant prevalence ofIgA nephropathy. With strengthened product protection we are even betterpositioned to attract partners and thereby reach out to patients in Asia."
Pharmalink AB previously announced highly promising results from aplanned interim analysis of an ongoing open Phase II trial which was designedto evaluate the efficacy and safety of Nefecon(R) in IgA nephropathy, aglomerulonephritis leading to end-stage renal disease. The interim resultswere confirmed in the final results obtained in early 2009. Nefecon(R) is anoral small molecule product which downregulates the inflammatory process inthe kidneys. It is being co-developed by Pharmalink and Archimedes Pharmaunder a partnership agreed in January 2004 to bring the product candidate toproof-of-concept.
The concept underlying the renal disease product candidate Nefecon is apatented invention by Professors Bengt Fellstrom and Roger Hallgren atUppsala University, Sweden. It is delivered using Archimedes' proprietaryTARGIT(R) drug delivery technology which enables the localized delivery ofdrugs to the lower small intestine or colonic regions of the gut. Archimedesis providing access to the TARGIT platform and providing all trial suppliesof Nefecon. Pharmalink is responsible for the management of the clinicaltrials.
Pharmalink AB is a privately held Swedish specialty pharma company thatdevelops proprietary pharmaceutical products in fields of unmet medical need.Pharmalink has adopted a reformulation/repurposing strategy and has a vastinternational network of physicians, biotech companies, CMOs, CROs andspecialist consultants. Pharmalink has a track record of introducing morethan 15 pharmaceutical products to market. Pharmalink currently has threeclinical phase development projects mature for out-licensing: Nefecon(R), aneffective treatment of IgA nephropathy; Xepol(R), the first effectivetreatment of neurology indication post-polio syndrome; and Busulipo(TM), asafer alternative for myeloablation prior to bone marrow transplantation.Pharmalink also seeks to refill its development pipeline by in-licensing.
About Archimedes Pharma
Archimedes Pharma ("Archimedes") is a pan-European specialtypharmaceutical company marketing and selling an expanding portfolio ofspecialist products to hospital-based prescribers in major Europeanterritories. Archimedes is also developing a robust, high value pipeline ofin-house products in pain, Parkinson's disease and critical care. It appliesits world-class drug delivery technologies to proven molecules which have yetto achieve their market potential due to their current mode of delivery. Thisapproach reduces the company's development risk, while delivering significantclinical and commercial benefits. The Group's lead development product isNasalFent(R), an innovative and highly differentiated fentanyl citrate nasalspray, for the rapid relief of breakthrough cancer pain. Archimedestechnologies - ChiSys(R), PecSys(TM) and TARGIT(R) - are used in a number ofpartnered products in late-stage clinical development. TARGIT is Archimedes'proprietary technology for the delivery of drugs to specific regions of thelarge intestine or the local treatment of disease, an area of great interestto the pharmaceutical industry. The TARGIT system offers the option ofdelivering high local concentrations of drug, which are ideal for the topicaltreatment of diseases such as ulcerative colitis, Crohn's disease, irritablebowel syndrome and bacterial infections. The ability of TARGIT to reliablydeliver drugs into the lower GIT has been demonstrated in numerous clinicalstudies.For further information, please contact: Pharmalink: Johan Haggblad, Managing Director, +46(0)70-668-0644 Email: email@example.com http://www.pharmalink.se Archimedes Pharma: Michael Clark, +44-118-931-5077 http://www.archimedespharma.com Citigate Dewe Rogerson (Pharmalink): Chris Gardner/Nina Enegren, +44-207-638-9571 CapitalMSL (Archimedes): Mary Clark, Tel: +44-207-3075330
SOURCE Pharmalink AB
You May Also Like